Loading
Lung Cancer Research Studies / Neuroendocrine Tumor Research Advances · Journal article
Science Advances · August 12, 2026
Raises a question worth testing. It does not answer one.
This proteogenomic analysis of 107 LCNEC tumors identifies three molecular subtypes and proposes IL-33 as a therapeutic biomarker associated with enhanced T cell infiltration. PEGylated recombinant IL-33 shows prolonged circulation and immune activity in cynomolgus monkeys and mouse models, but no clinical efficacy data in humans are presented.
Proteogenomic characterization study with preclinical validation. 107 patients with pulmonary large-cell neuroendocrine carcinoma (LCNEC) or combined LCNEC with other NSCLC subtypes. Specific eligibility criteria, histology confirmation method, and clinical setting not stated.. Intervention: Proteogenomic profiling; PEGylated recombinant IL-33 (rIL33) in preclinical models. n = 107.
107 patients studied: 81 pure LCNEC and 26 combined LCNEC APOBEC mutational signatures correlate with tumor initiation and immune suppression KEAP1 mutations correlate with metabolic reprogramming in LCNEC combined with NSCLC
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work provides molecular insight into LCNEC biology and proposes IL-33-based immunotherapy as a novel strategy. However, clinical utility remains unvalidated; therapeutic proposals require phase 1 human trials before clinical recommendation.
Proteogenomic characterization study identifying molecular subtypes and proposing IL-33 as a therapeutic target, with preclinical validation in animal models but no clinical efficacy data in patients.
As stated by the source record.
Quoted from the source exactly as published.
This work provides molecular insight into LCNEC biology and proposes IL-33-based immunotherapy as a novel strategy. However, clinical utility remains unvalidated; therapeutic proposals require phase 1 human trials before clinical recommendation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare yet highly aggressive subtype of non-small cell lung carcinoma (NSCLC) with limited therapeutic options. We conduct a comprehensive proteogenomic analysis of LCNEC using tumors and paired normal adjacent tissues from 107 patients (81 pure LCNEC and 26 combined LCNEC). APOBEC mutational signatures strongly correlate processes of tumor initiation and immune suppression, and KEAP1 mutations correlate with metabolic reprogramming in LCNEC combined with NSCLC. A conflicting relationship is observed between neuroendocrine and immune phenotypes. We identify three LCNEC subtypes with unique prognosis features, microenvironment dysregulation, genetic alterations, and potential therapeutic targets. Interleukin-33 (IL-33) emerges as a critical therapeutic biomarker associated with enhanced T cell infiltration and antitumor activity. We further optimize recombinant IL-33 (rIL33) with site-directed mutagenesis and develop PEGylated rIL33, demonstrating its prolonged circulation time in cynomolgus monkeys and superior immune agonist activity in mouse models. Overall, this study offers insights into LCNEC biology and provides promising innovative immunoagonist therapy strategies for lung cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.